BIOMAT Database Logo BIOMAT Database Logo

HLA-DR restriction-fragment-length polymorphisms in narcolepsy. 1987

J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
Department of Medical Microbiology, Stanford University School of Medicine, California.

Seventeen white patients from the Stanford Sleep Disorders Clinic complaining of excessive daytime somnolence (EDS) were selected for restriction-fragment-length polymorphism (RFLP) studies. Fourteen of the patients with clinically diagnosed narcolepsy were seropositive for DR2. RFLP analysis of these patients compared with a homozygous DR2-Dw2 cell line failed to reveal any polymorphism when digested with six restriction endonucleases and hybridized with three different cDNA probes. None of the three patients with central nervous system hypersomnia, a syndrome similar to narcolepsy, were DR2-positive. We conclude that any polymorphism of the DR beta, DQ alpha, or DQ beta genes of DR2 narcoleptics that might distinguish them from DR2 normals cannot be resolved through RFLP analysis.

UI MeSH Term Description Entries
D008285 Major Histocompatibility Complex The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. Histocompatibility Complex,Complex, Histocompatibility,Complex, Major Histocompatibility,Complices, Histocompatibility,Complices, Major Histocompatibility,Histocompatibility Complex, Major,Histocompatibility Complices,Histocompatibility Complices, Major,Major Histocompatibility Complices
D009290 Narcolepsy A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7) Gelineau Syndrome,Narcolepsy-Cataplexy Syndrome,Paroxysmal Sleep,Gelineau's Syndrome,Narcoleptic Syndrome,Gelineau's Syndromes,Gelineaus Syndrome,Narcolepsy Cataplexy Syndrome,Narcolepsy-Cataplexy Syndromes,Narcoleptic Syndromes,Sleep, Paroxysmal,Syndrome, Gelineau,Syndrome, Gelineau's,Syndrome, Narcolepsy-Cataplexy,Syndrome, Narcoleptic,Syndromes, Gelineau's,Syndromes, Narcolepsy-Cataplexy,Syndromes, Narcoleptic
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D006681 HLA-D Antigens Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology. Antigens, HLA-D,Class II Human Antigens,HLA-Dw Antigens,Human Class II Antigens,Ia-Like Antigens, Human,Immune Response-Associated Antigens, Human,Immune-Associated Antigens, Human,Immune-Response Antigens, Human,HLA-D,HLA-Dw,Immune Response Associated Antigens, Human,Antigens, HLA D,Antigens, HLA-Dw,Antigens, Human Ia-Like,Antigens, Human Immune-Associated,Antigens, Human Immune-Response,HLA D Antigens,HLA Dw Antigens,Human Ia-Like Antigens,Human Immune-Associated Antigens,Human Immune-Response Antigens,Ia Like Antigens, Human,Immune Associated Antigens, Human,Immune Response Antigens, Human
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015802 HLA-DR2 Antigen A broad specificity HLA-DR antigen that is associated with HLA-DRB1 CHAINS encoded by DRB1*01:15 and DRB1*01:16 alleles. HLA-DR2,Antigen, HLA-DR2,HLA DR2 Antigen

Related Publications

J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
HLA-DR: serology versus restriction fragment length polymorphism.
January 1991, Vox sanguinis,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
Linkage of HLA-DR beta specific restriction fragment length polymorphisms with Graves' disease.
October 1988, Acta endocrinologica,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
HLA class II DR, DQ, and DP restriction fragment length polymorphisms in rheumatoid arthritis.
April 1989, Annals of the rheumatic diseases,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
HLA-DQ restriction fragment length polymorphisms in myasthenia gravis.
January 1987, Annals of the New York Academy of Sciences,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
HLA-DR genotyping by restriction fragment length polymorphism analyses.
January 1985, Immunogenetics,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
HLA-DR beta, -DQ alpha, and -DQ beta restriction fragment length polymorphisms in multiple sclerosis.
May 1989, Journal of neuroscience research,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
DNATYPE--a personal computer program for HLA-DR typing based upon restriction fragment length polymorphisms.
July 1986, Tissue antigens,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
Restriction fragment length polymorphism in canine narcolepsy.
January 1989, Immunogenetics,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
Restriction fragment length polymorphisms.
January 1987, Methods in enzymology,
J D Holloman, and J I Bell, and T S Kilduff, and W C Dement, and C Guilleminault, and H O McDevitt
Restriction fragment length polymorphisms and an HLA-DRw52-associated split.
February 1988, Human immunology,
Copied contents to your clipboard!